LBCL-话题@MedSci

#LBCL#

54篇内容 | 2353人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2021249, encodeId=93062021249ca, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：在利妥昔单抗时代，结外DLBCL的临床特征和预后, objectType=article, longId=198980, objectId=03fb1989807e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03fb1989807e, replyNumber=0, likeNumber=71, createdTime=2021-07-17, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03fb1989807e, moduleTitle=Blood：在利妥昔单抗时代，结外DLBCL的临床特征和预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03fb1989807e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021246, encodeId=2db6202124682, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：Avadomide(CC-122)单药治疗难治性/复发性DLBCL的疗效和安全性, objectType=article, longId=187353, objectId=19ef18e35330, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19ef18e35330, replyNumber=0, likeNumber=68, createdTime=2020-04-08, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19ef18e35330, moduleTitle=Blood：Avadomide(CC-122)单药治疗难治性/复发性DLBCL的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19ef18e35330)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021248, encodeId=8702202124897, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Lancet oncol：R-CHOP联合甲氨蝶呤和鞘内化疗治疗新确诊的IVLBCL的疗效和安全性, objectType=article, longId=190230, objectId=fcd3190230c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcd3190230c9, replyNumber=0, likeNumber=0, createdTime=2021-01-05, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcd3190230c9, moduleTitle=Lancet oncol：R-CHOP联合甲氨蝶呤和鞘内化疗治疗新确诊的IVLBCL的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcd3190230c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021242, encodeId=7afd202124235, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：不同LBCL亚型间的分子异质性, objectType=article, longId=183342, objectId=0a081833423e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a081833423e, replyNumber=0, likeNumber=53, createdTime=2020-03-27, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a081833423e, moduleTitle=Blood：不同LBCL亚型间的分子异质性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a081833423e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021244, encodeId=87272021244a2, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=tafasitamab一线治疗DLBCL的I期临床研究已正式开展, objectType=article, longId=185457, objectId=3ff918545e72, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ff918545e72, replyNumber=0, likeNumber=72, createdTime=2020-05-12, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ff918545e72, moduleTitle=tafasitamab一线治疗DLBCL的I期临床研究已正式开展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ff918545e72)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021245, encodeId=ba822021245d8, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：高起始总代谢瘤体积有助于鉴别超高危险的DLBCL人群, objectType=article, longId=187114, objectId=435d18e1145d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=435d18e1145d, replyNumber=0, likeNumber=89, createdTime=2020-12-04, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=435d18e1145d, moduleTitle=Blood：高起始总代谢瘤体积有助于鉴别超高危险的DLBCL人群, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=435d18e1145d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021241, encodeId=15582021241eb, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=【2019ASH抢先看】R2-miniCHOP能否改善≥80岁DLBCL患者OS呢？答案可能在你意料之中, objectType=article, longId=182706, objectId=36ab182e0678, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36ab182e0678, replyNumber=0, likeNumber=82, createdTime=2020-09-13, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36ab182e0678, moduleTitle=【2019ASH抢先看】R2-miniCHOP能否改善≥80岁DLBCL患者OS呢？答案可能在你意料之中, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36ab182e0678)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021239, encodeId=acf42021239e3, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=黄慧强教授：DLBCL 无化疗方案，一项引人关注的尝试, objectType=article, longId=171146, objectId=ca511e114698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca511e114698, replyNumber=0, likeNumber=54, createdTime=2020-06-07, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca511e114698, moduleTitle=黄慧强教授：DLBCL 无化疗方案，一项引人关注的尝试, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca511e114698)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021240, encodeId=be9220212403b, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：依鲁替尼联合来那度胺和利妥昔单抗用于复发性/难治性非生发中心B细胞DLBCL的疗效可期, objectType=article, longId=176195, objectId=60091e619534, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60091e619534, replyNumber=0, likeNumber=73, createdTime=2020-06-18, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60091e619534, moduleTitle=Blood：依鲁替尼联合来那度胺和利妥昔单抗用于复发性/难治性非生发中心B细胞DLBCL的疗效可期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60091e619534)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021238, encodeId=59172021238ef, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=王亮教授：R-CHOP一线治疗DLBCL——一直被挑战，至今从未被超越！, objectType=article, longId=169070, objectId=3a321690e0a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a321690e0a2, replyNumber=0, likeNumber=62, createdTime=2019-10-16, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a321690e0a2, moduleTitle=王亮教授：R-CHOP一线治疗DLBCL——一直被挑战，至今从未被超越！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a321690e0a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021236, encodeId=1dfa20212360d, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Clin Cancer Res:弥漫性大B细胞淋巴瘤（DLBCL）治疗耐药新机制, objectType=article, longId=164689, objectId=774b16468924, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=774b16468924, replyNumber=0, likeNumber=90, createdTime=2019-07-09, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=774b16468924, moduleTitle=Clin Cancer Res:弥漫性大B细胞淋巴瘤（DLBCL）治疗耐药新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=774b16468924)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021237, encodeId=89c4202123e77, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=II期研究的更新数据以评估DPX-Survivac与Pembrolizumab联合治疗DLBCL的有效性, objectType=article, longId=165418, objectId=11561654182e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11561654182e, replyNumber=0, likeNumber=62, createdTime=2019-05-12, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11561654182e, moduleTitle=II期研究的更新数据以评估DPX-Survivac与Pembrolizumab联合治疗DLBCL的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11561654182e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021235, encodeId=e25420212357c, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=诺华Kymriah治疗DLBCL全新14个月随访数据：完全缓解率40%, objectType=article, longId=141068, objectId=eda7141068fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eda7141068fb, replyNumber=0, likeNumber=70, createdTime=2018-12-03, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eda7141068fb, moduleTitle=诺华Kymriah治疗DLBCL全新14个月随访数据：完全缓解率40%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eda7141068fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021233, encodeId=65202021233c9, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=【2018EHA抢先看】年龄或许不是问题！高龄DLBCL患者也可从蒽环类方案中获益, objectType=article, longId=139493, objectId=415913949326, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=415913949326, replyNumber=0, likeNumber=61, createdTime=2018-07-08, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=415913949326, moduleTitle=【2018EHA抢先看】年龄或许不是问题！高龄DLBCL患者也可从蒽环类方案中获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=415913949326)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021234, encodeId=12912021234f2, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：HSP110通过稳定MyD88维持ABL-DLBCL的NF-κB信号, objectType=article, longId=140196, objectId=c12e140196fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c12e140196fc, replyNumber=0, likeNumber=97, createdTime=2019-04-07, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c12e140196fc, moduleTitle=Blood：HSP110通过稳定MyD88维持ABL-DLBCL的NF-κB信号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c12e140196fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021231, encodeId=6d2320212317d, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=重复：J Clin Oncol：来那度胺用于DLBCL老年患者一线维持治疗结果喜人, objectType=article, longId=110434, objectId=236e110434c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=236e110434c4, replyNumber=0, likeNumber=76, createdTime=2018-05-08, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=236e110434c4, moduleTitle=重复：J Clin Oncol：来那度胺用于DLBCL老年患者一线维持治疗结果喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=236e110434c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021232, encodeId=e9f820212324b, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：对于限制期DLBCL患者，R-CHOP化疗联合放射治疗的效果并不优于单纯R-CHOP化疗。, objectType=article, longId=117566, objectId=76bc11e5667f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76bc11e5667f, replyNumber=0, likeNumber=62, createdTime=2018-01-21, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76bc11e5667f, moduleTitle=Blood：对于限制期DLBCL患者，R-CHOP化疗联合放射治疗的效果并不优于单纯R-CHOP化疗。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76bc11e5667f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021229, encodeId=5cee2021229b9, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=JCO：来那度胺+R-CHOP维持治疗，老年DLBCL患者预后如何？, objectType=article, longId=100056, objectId=c37410005683, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c37410005683, replyNumber=0, likeNumber=69, createdTime=2018-04-09, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c37410005683, moduleTitle=JCO：来那度胺+R-CHOP维持治疗，老年DLBCL患者预后如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c37410005683)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021230, encodeId=a3af2021230f5, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Br J Haematol：现代治疗中DLBCL后原发恶性肿瘤的发病率, objectType=article, longId=105797, objectId=fc63105e9745, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc63105e9745, replyNumber=0, likeNumber=63, createdTime=2017-09-26, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc63105e9745, moduleTitle=Br J Haematol：现代治疗中DLBCL后原发恶性肿瘤的发病率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc63105e9745)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021228, encodeId=861320212282c, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood:一项LYSA研究：利妥昔单抗暴露受基线代谢肿瘤体积影响并可预测DLBCL患者疗效, objectType=article, longId=90981, objectId=fe4c90981ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe4c90981ab, replyNumber=0, likeNumber=67, createdTime=2017-04-10, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe4c90981ab, moduleTitle=Blood:一项LYSA研究：利妥昔单抗暴露受基线代谢肿瘤体积影响并可预测DLBCL患者疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe4c90981ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

LBCL

2020-05-29

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：在利妥昔单抗时代，结外DLBCL的临床特征和预后

2021-07-17

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：Avadomide(CC-122)单药治疗难治性/复发性DLBCL的疗效和安全性

2020-04-08

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Lancet oncol：R-CHOP联合甲氨蝶呤和鞘内化疗治疗新确诊的IVLBCL的疗效和安全性

2021-01-05

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：不同LBCL亚型间的分子异质性

2020-03-27

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

tafasitamab一线治疗DLBCL的I期临床研究已正式开展

2020-05-12

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：高起始总代谢瘤体积有助于鉴别超高危险的DLBCL人群

2020-12-04

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

【2019ASH抢先看】R2-miniCHOP能否改善≥80岁DLBCL患者OS呢？答案可能在你意料之中

2020-09-13

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

黄慧强教授：DLBCL 无化疗方案，一项引人关注的尝试

2020-06-07

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：依鲁替尼联合来那度胺和利妥昔单抗用于复发性/难治性非生发中心B细胞DLBCL的疗效可期

2020-06-18

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

王亮教授：R-CHOP一线治疗DLBCL——一直被挑战，至今从未被超越！

2019-10-16

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Clin Cancer Res:弥漫性大B细胞淋巴瘤（DLBCL）治疗耐药新机制

2019-07-09

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

II期研究的更新数据以评估DPX-Survivac与Pembrolizumab联合治疗DLBCL的有效性

2019-05-12

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

诺华Kymriah治疗DLBCL全新14个月随访数据：完全缓解率40%

2018-12-03

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

【2018EHA抢先看】年龄或许不是问题！高龄DLBCL患者也可从蒽环类方案中获益

2018-07-08

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：HSP110通过稳定MyD88维持ABL-DLBCL的NF-κB信号

2019-04-07

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

重复：J Clin Oncol：来那度胺用于DLBCL老年患者一线维持治疗结果喜人

2018-05-08

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：对于限制期DLBCL患者，R-CHOP化疗联合放射治疗的效果并不优于单纯R-CHOP化疗。

2018-01-21

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

JCO：来那度胺+R-CHOP维持治疗，老年DLBCL患者预后如何？

2018-04-09

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Br J Haematol：现代治疗中DLBCL后原发恶性肿瘤的发病率

2017-09-26

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood:一项LYSA研究：利妥昔单抗暴露受基线代谢肿瘤体积影响并可预测DLBCL患者疗效

2017-04-10

科室
- - 订阅+
  - 更多科室
工具
服务